Skip to content
Parkinson's News Today logo Newsletter
Newsletter
  • About Parkinson's
    What is Parkinson’s disease?
    Causes
    Diagnosis
    Symptoms
    • Motor symptoms
    • Non-motor symptoms
    Living with Parkinson’s
    Types
    Treatments
    • Approved treatments
    • Experimental treatments
    • Non-drug treatments
  • Expert voices
    Integrative medicine
    Deep brain stimulation
    Safe exercise
    Cannabis and Parkinson’s symptoms
    Speech difficulties
    Diet and nutrition
    Caring for mental health
    Managing sex and intimacy issues
  • Parkinson's psychosis guide
    Patients
    • What is psychosis?
    • Talking to your doctor about psychosis
    • Perspective: Living with psychosis
    • Emotional and mental health
    • Psychosis risk factors
    Caregivers of spouses
    • Early signs of psychosis
    • Preparing for psychosis
    • Perspective: Supporting your spouse
    • Respite care
    • Hallucinations, delusions, illusions
    Caregivers of parents
    • Talking to a parent with psychosis
    • Psychosis care options
    • Perspective: Caring for a parent
    • Do’s and don’ts
    • Remote Parkinson’s care
    In focus video series
    • Managing Parkinson’s psychosis
    • Strategies for managing psychosis
    • Early signs of psychosis
    • Discerning Parkinson's-related psychosis
  • News & Research
  • Columns
    The Bright Side – Jamie Askari
    Living My Best Life – Christine Scheer
    The Love Factor – Chukwuemeka Uchebuakor
    PD: The WE Journey – Jill Hammergren
    The Impatient Patient – Doc Irish
    Shaking Things Up — Mary Beth Skylis
    Unshakable Optimist – Mollie Lombardi
    Archived columns
    • Embrace the Shake — Samantha Felder
    • Life, Lemons, and Lemonade — Lori DePorter
    • Possibilities With Parkinson’s — Dr. C
    • Resilient: Living Relentlessly — Jo Gambosi
  • Forums
  • Advocacy partners
  • What can we help you find today?

February 2, 2024 News by Patricia Inácio, PhD

Topline buntanetap trial data in early-stage Parkinson’s due ‘soon’

Topline data from a Phase 3 clinical trial of buntanetap in early-stage Parkinson’s disease patients is expected soon, according to Annovis Bio, the therapy’s developer. Initially planned for the end of January, ongoing analysis to ensure “clean data” that are accurate and reliable was cited as the reason…

December 10, 2019 News by Joana Carvalho, PhD

Novartis’ Tasigna Fails to Show Clinically Meaningful Benefits in Parkinson’s, Phase 2 Trial Shows

Tasigna (nilotinib), an approved leukemia medication being tested as a repurposed treatment for Parkinson’s disease, failed to show any clinically meaningful benefits in a Phase 2 trial, the study’s steering committee announced. Although an announcement of the study’s topline data was originally planned for 2020, the trial’s steering…

Recent Posts

  • Study findings ‘lay foundation’ for targeted therapies in Parkinson’s
  • MJFF expands training program for movement disorder specialists
  • RNA-editing enzyme may be novel treatment target in Parkinson’s
  • Compound ID’d that may reduce Parkinson’s brain inflammation
  • Bringing Parkinson’s awareness to underserved rural communities


Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: info@bionews.com
Phone: 1-800-936-1363

  • About Us
  • Leadership
  • Our Culture
  • Editorial Policy
  • Advertising Policy
  • Corrections Policy
  • Terms of Service
  • Privacy Policy
  • Careers
  • Contact Us
Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Copyright © 2013-2025 All rights reserved.